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Commentary 
 
There appears to be little controversy about the use of current brain atrophy measures as 
a guide to therapeutic decisions in multiple sclerosis (MS): Zivadinov, Dwyer and Bergs-
land (for), and Barkhof (against), appear to agree that the methods now available are not 
useable in clinical practice, and that there is much still to be done before they can contrib-
ute usefully to treatment choices. I agree with them. However, this does not mean that I 
think we should give up on brain atrophy measures, given the alternatives, and the emer-
gence of treatments that may actually slow progression in MS. Progressive MS, and the 
neurodegeneration thought to underly a substantial part of it, is difficult to detect clinically. 
The onset of progression can take years to become clear [Sand et al. 2014], and in treat-
ment trials much larger cohorts are required to detect effects using clinical compared with 
  
magnetic resonance imaging (MRI) measures [Miller, Altmann and Chard, 2012]. As such, 
clinical measures also fall far short of the ideal. 
 
Barkhof, and Zivadinov and colleagues, highlight the mismatch between the established 
role of brain atrophy measures in early phase treatment trials, and the possible part they 
may play tailoring treatments to individual people with MS. However, given that the bal-
ance between efficacy, side effects and costs differ between treatments, there may be 
scope to use these measures flexibly in clinical practice. For safe and cost-effective drugs, 
the thresholds for treatment may be low, seeking to identify the majority who will benefit 
while still including some who will not. For treatments with a greater risk of harm, or great-
er costs, the thresholds may be higher, selecting only those who are most likely to benefit. 
 
Another factor to consider is how quickly a decision about treatment needs to be made. In 
contrast to MS relapses - where events can unfold over hours to days - the consequences 
of neurodegeneration evolve over months to years. Given this, as Zivadinov et al. observe, 
while optimally treatments that prevent this would be started as early as possible, brain at-
rophy measures may still be of value guiding treatment decisions even if they take several 
years to do so. Relevant to this is the trade off between time and sensitivity to change that 
is very apparent when we consider the use of brain atrophy measures in clinical trials. Us-
ing SIENA - a method that it often used in MS trials - to detect a 50% treatment effect with 
80% power, over 1 year about 50 people would be required in each treatment arm, while 
over 2 years this drops to about 30 people [Altmann et al. 2009]. 
 
It is also worth recalling how MRI is currently used in MS clinical practice, as a guide to 
how brain atrophy measures may be used in future. I think it is unlikely that they will be 
employed in isolation, but rather as an adjunct to, or to augment, clinical and other MRI 
measures. The McDonald MS diagnostic criteria [Polman et al. 2011] are a superb exam-
ple of the practical role MRI can play in clinical decision making, and they do not rely solely 
on MRI findings to establish a diagnosis. Similarly, Rio and colleagues [2009] have shown 
that a combination of MRI and clinical findings, rather than either alone, is better able to 
predict disability progression in people with MS taking beta-interferon. However, as noted 
by Zivadinov and colleagues, and Barkhof, even if we are able to clearly show that brain 
atrophy measures can contribute usefully to clinical decision making, they still need to be 
easily implemented on standard MRI machines, readily interpretable by clinicians, and ac-
ceptable to regulators. I suspect that we will not see them in use soon. 
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